Abstract
Human pancreatic islet transplantation has recently been shown to be successful in replacing pancreatic endocrine function into type 1 diabetic recipients. A major drawback, however, is the high amount of pancreatic ß cells required to render one single patient insulin-independent. Given the shortage of human ß cell donors, the majority of type 1 diabetic patients remain excluded from this therapeutic option. High number of islets are requested since substantial islet cell death and dysfunction occur within the first few hours and days after islet transplantation. Impaired vascularization of the engraft, the non-specific inflammatory reaction at the site of transplantation, together with the presence of active or memory autoimmune responses to islet autoantigens and allogeneic recognition contribute to apoptosis of ß cells and subsequent early graft function loss. This review will focus on ex vivo engineering of the islet graft by gene transfer to improve islet engraftment. An overview of currently used gene transfer techniques will be given and their potential will be discussed.
Keywords: ex vivo gene transfer, islets, engraftment, angiogenesis, diabetes
Current Pharmaceutical Design
Title: Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Volume: 11 Issue: 22
Author(s): S. Van Linthout and P. Madeddu
Affiliation:
Keywords: ex vivo gene transfer, islets, engraftment, angiogenesis, diabetes
Abstract: Human pancreatic islet transplantation has recently been shown to be successful in replacing pancreatic endocrine function into type 1 diabetic recipients. A major drawback, however, is the high amount of pancreatic ß cells required to render one single patient insulin-independent. Given the shortage of human ß cell donors, the majority of type 1 diabetic patients remain excluded from this therapeutic option. High number of islets are requested since substantial islet cell death and dysfunction occur within the first few hours and days after islet transplantation. Impaired vascularization of the engraft, the non-specific inflammatory reaction at the site of transplantation, together with the presence of active or memory autoimmune responses to islet autoantigens and allogeneic recognition contribute to apoptosis of ß cells and subsequent early graft function loss. This review will focus on ex vivo engineering of the islet graft by gene transfer to improve islet engraftment. An overview of currently used gene transfer techniques will be given and their potential will be discussed.
Export Options
About this article
Cite this article as:
Linthout Van S. and Madeddu P., Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function, Current Pharmaceutical Design 2005; 11 (22) . https://dx.doi.org/10.2174/1381612054546743
DOI https://dx.doi.org/10.2174/1381612054546743 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Device Therapies: New Indications and Future Directions
Current Cardiology Reviews Historical Aspects and Relevance of the Human Coronary Collateral Circulation
Current Cardiology Reviews Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?
Current Vascular Pharmacology Editorial [Hot Topic: Analgesic Drug Discovery: Promising Future (Guest Editor: Anindya Bhattacharya)]
Current Pharmaceutical Biotechnology Wharton’s Jelly or Bone Marrow Mesenchymal Stromal Cells Improve Cardiac Function Following Myocardial Infarction for More Than 32 Weeks in a Rat Model: A Preliminary Report
Current Stem Cell Research & Therapy New-Onset Hyperglycemia and Acute Coronary Syndrome: A Systematic Overview and Meta-Analysis
Current Diabetes Reviews Editorial [Hot Topic: Matrix Metalloproteinases in Cardiovascular Disease (Guest Editors: N. Papageorgiou & D. Tousoulis)]
Current Topics in Medicinal Chemistry Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Recent Studies of Antioxidant Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Therapeutic Management Strategies for Type 2 Diabetes
Current Diabetes Reviews On the Interaction Between Human IQGAP1 and Actin
Protein & Peptide Letters Method Development & Validation of LCMS/MS for Atorvastatin and Olmesartan in Human Plasma to Trace Drug Interaction of Formulation
Current Pharmaceutical Analysis Cold Virus Fusion or Stopping Fusion Cold – Inhibitors of the Human Respiratory Syncytial Virus F Protein
Recent Patents on Anti-Infective Drug Discovery Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with Type 2 Diabetes?
Vascular Disease Prevention (Discontinued) Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Effectiveness and Safety of Digoxin on Chronic Heart Failure
Current Pharmaceutical Analysis